Treatment

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Expanding research into biomarkers for RPD differentiation

TREM2 as a target for disease modification in Alzheimer’s disease

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Symptomatic versus disease modifying treatments

Defining subgroups of patients with subjective cognitive decline more likely to progress

European task force recommendations: shifting memory clinics towards prevention

Distinguishing between disease modifying and symptomatic effects in clinical trials

Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease

Past and future of immunotherapy in Alzheimer’s disease

Gotcha! A therapy app for proper name anomia in dementia

Lecanemab: drawbacks to consider

Lecanemab: a review